<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Nutr</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Nutr</journal-id><journal-id journal-id-type="publisher-id">BJN</journal-id><journal-title-group><journal-title>The British Journal of Nutrition</journal-title></journal-title-group><issn pub-type="ppub">0007-1145</issn><issn pub-type="epub">1475-2662</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26348767</article-id><article-id pub-id-type="pmc">4594054</article-id><article-id pub-id-type="doi">10.1017/S0007114515002822</article-id><article-id pub-id-type="pii">S0007114515002822</article-id><article-id pub-id-type="publisher-id">00282</article-id><article-categories><subj-group subj-group-type="heading"><subject>Full Papers</subject></subj-group><subj-group subj-group-type="section"><subject>Human and Clinical Nutrition</subject></subj-group></article-categories><title-group><article-title>Cocoa flavanol intake improves endothelial function and Framingham Risk Score
in healthy men and women: a randomised, controlled, double-masked trial: the Flaviola
Health Study</article-title><alt-title alt-title-type="left-running">R. Sansone <italic>et al.</italic></alt-title><alt-title alt-title-type="right-running">Flavanols and cardiovascular health</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sansone</surname><given-names>Roberto</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rodriguez-Mateos</surname><given-names>Ana</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Heuel</surname><given-names>Jan</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Falk</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Schuler</surname><given-names>Dominik</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wagstaff</surname><given-names>Rabea</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kuhnle</surname><given-names>Gunter G. C.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Spencer</surname><given-names>Jeremy P. E.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Schroeter</surname><given-names>Hagen</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Merx</surname><given-names>Marc W.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kelm</surname><given-names>Malte</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Heiss</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><collab>for the Flaviola Consortium, European Union 7th Framework Program</collab></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Division of Cardiology</addr-line>, <addr-line>Pulmonology, and
Vascular Medicine</addr-line>, Medical Faculty, <institution>University
Duesseldorf</institution>, <addr-line>40225 Duesseldorf</addr-line>,
<country>Germany</country></aff><aff id="aff2"><label>2</label><addr-line>Department of Food and Nutritional Sciences</addr-line>,
<institution>University of Reading</institution>, <addr-line>Reading</addr-line>,
<country>UK</country></aff><aff id="aff3"><label>3</label><addr-line>Mars Inc.</addr-line>, <addr-line>McLean, VA</addr-line>,
<country>USA</country></aff><aff id="aff4"><label>4</label><addr-line>Cardiovascular Research Institute Duesseldorf</addr-line>,
Medical Faculty, <institution>University Duesseldorf</institution>, <addr-line>40225
Duesseldorf</addr-line>, <country>Germany</country></aff><author-notes><corresp id="cor1"><label>*</label><bold>Corresponding author:</bold> Dr C. Heiss, fax +<fax>49 211 811 8812</fax>, email
<email>christian.heiss@med.uni-duesseldorf.de</email></corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>9</month><year>2015</year></pub-date><pub-date pub-type="ppub"><day>28</day><month>10</month><year>2015</year></pub-date><volume>114</volume><issue>8</issue><fpage>1246</fpage><lpage>1255</lpage><history><date date-type="received"><day>01</day><month>3</month><year>2015</year></date><date date-type="rev-recd"><day>31</day><month>5</month><year>2015</year></date><date date-type="accepted"><day>22</day><month>6</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; The Authors 2015</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>The Authors</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p><!--CREATIVE COMMONS-->This is an Open Access article, distributed under the terms of the Creative
Commons Attribution licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits
unrestricted re-use, distribution, and reproduction in any medium, provided the original
work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0007114515002822a.pdf"/><abstract abstract-type="normal"><p>Cocoa flavanol (CF) intake improves endothelial function in patients with cardiovascular
risk factors and disease. We investigated the effects of CF on surrogate markers of
cardiovascular health in low risk, healthy, middle-aged individuals without history, signs
or symptoms of CVD. In a 1-month, open-label, one-armed pilot study, bi-daily ingestion of
450 mg of CF led to a time-dependent increase in endothelial function (measured as
flow-mediated vasodilation (FMD)) that plateaued after 2 weeks. Subsequently, in a
randomised, controlled, double-masked, parallel-group dietary intervention trial
(Clinicaltrials.gov: NCT01799005), 100 healthy, middle-aged (35&#x02013;60 years) men and women
consumed either the CF-containing drink (450 mg) or a nutrient-matched CF-free control
bi-daily for 1 month. The primary end point was FMD. Secondary end points included plasma
lipids and blood pressure, thus enabling the calculation of Framingham Risk Scores and
pulse wave velocity. At 1 month, CF increased FMD over control by 1&#x000b7;2 % (95 % CI 1&#x000b7;0, 1&#x000b7;4
%). CF decreased systolic and diastolic blood pressure by 4&#x000b7;4 mmHg (95 % CI 7&#x000b7;9, 0&#x000b7;9 mmHg)
and 3&#x000b7;9 mmHg (95 % CI 6&#x000b7;7, 0&#x000b7;9 mmHg), pulse wave velocity by 0&#x000b7;4 m/s (95 % CI 0&#x000b7;8, 0&#x000b7;04
m/s), total cholesterol by 0&#x000b7;20 mmol/l (95 % CI 0&#x000b7;39, 0&#x000b7;01 mmol/l) and LDL-cholesterol by
0&#x000b7;17 mmol/l (95 % CI 0&#x000b7;32, 0&#x000b7;02 mmol/l), whereas HDL-cholesterol increased by 0&#x000b7;10 mmol/l
(95 % CI 0&#x000b7;04, 0&#x000b7;17 mmol/l). By applying the Framingham Risk Score, CF predicted a
significant lowering of 10-year risk for CHD, myocardial infarction, CVD, death from CHD
and CVD. In healthy individuals, regular CF intake improved accredited cardiovascular
surrogates of cardiovascular risk, demonstrating that dietary flavanols have the potential
to maintain cardiovascular health even in low-risk subjects.</p></abstract><kwd-group><title>Key words</title><kwd>Flow-mediated dilation</kwd><kwd>Cardiovascular health</kwd><kwd>Flavanols</kwd><kwd>Blood pressure</kwd></kwd-group><kwd-group kwd-group-type="abbreviations"><title>Abbreviations</title><compound-kwd><compound-kwd-part content-type="abbrev">BP</compound-kwd-part><compound-kwd-part content-type="expansion">blood pressure</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="abbrev">CF</compound-kwd-part><compound-kwd-part content-type="expansion">cocoa flavanol</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="abbrev">DBP</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="abbrev">diastolic blood pressure</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="abbrev">FMD</compound-kwd-part><compound-kwd-part content-type="expansion">flow-mediated dilation</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="abbrev">PWV</compound-kwd-part><compound-kwd-part content-type="expansion">pulse wave velocity</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="abbrev">SBP</compound-kwd-part><compound-kwd-part content-type="expansion">systolic blood pressure</compound-kwd-part></compound-kwd></kwd-group><counts><fig-count count="2"/><table-count count="3"/><page-count count="10"/></counts></article-meta></front><body><p>Flavanols, a subgroup of dietary plant-derived bioactives, have gained increasing attention,
as clinical studies have shown that a higher intake of flavanol-containing foods can improve
arterial function in individuals at risk for CVD and with established CVD<sup>(</sup>
<xref rid="ref1" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="ref2" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>)</sup>. The mechanisms of action underlying the biological effects of flavanols are not
completely understood. However, flavanols are one of the few bioactives known today, for which
causality between intake and an improvement in arterial function has been formally
demonstrated<sup>(</sup>
<xref rid="ref3" ref-type="bibr">
<sup>3</sup>
</xref>
<sup>)</sup>. A recent meta-analysis of forty-two randomised controlled human dietary
intervention studies also demonstrated significant acute and chronic (up to 18 weeks)
flavanol-dependent cardiovascular benefits<sup>(</sup>
<xref rid="ref4" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>,</sup>
<xref rid="ref5" ref-type="bibr">
<sup>5</sup>
</xref>
<sup>)</sup>. The observed cardiovascular benefits include the recovery of endothelial
function, a decrease in blood pressure (BP) and improvements in lipids and insulin
resistance<sup>(</sup>
<xref rid="ref6" ref-type="bibr">
<sup>6</sup>
</xref>
<sup>)</sup>. For the most part, these effects have been studied in individuals at increased
cardiovascular risk, such as smokers, or those with established hypertension, diabetes,
hypercholesterolaemia and manifest coronary artery disease<sup>(</sup>
<xref rid="ref4" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>,</sup>
<xref rid="ref5" ref-type="bibr">
<sup>5</sup>
</xref>
<sup>)</sup>.</p><p>Whether or not the intake of cocoa flavanol (CF) has the potential to maintain and/or improve
cardiovascular health in individuals without CVD and those with low degrees of cardiovascular
risk, that is, healthy subjects, has not been evaluated. To yield meaningful results, studies
aimed at addressing this point ideally need to be conducted in the context of broader
age-range and include both sexes, and they need to be carried out for durations of 4 weeks or
longer<sup>(</sup>
<xref rid="ref7" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup>. Thus, in the present study, we sought to investigate the effects of dietary CF
intake on established surrogate markers of cardiovascular risk in healthy, middle-aged
individuals without history, signs or symptoms of CVD. As the primary end point, we selected
to measure endothelial function as flow-mediated dilation (FMD), and included assessments of
plasma lipids, BP and pulse wave velocity (PWV) as secondary end points. Using a
well-characterised CF-containing test drink and its CF-free control, we undertook a
randomised, double-masked, 1-month dietary CF intervention assessing the above end points. In
addition, based on applying the Framingham Risk Model we also aimed at providing an initial
evaluation of the potential for dietary CF in the context of primary CVD prevention.</p><sec sec-type="methods" id="sec1"><title>Methods</title><sec id="sec1-1" sec-type="general"><title>Study participants and study design</title><p>The study took place at the Division of Cardiology, Pulmonology and Vascular Medicine of
Duesseldorf University in Duesseldorf, Germany from February 2013 to August 2014. We
recruited subjects by word-to-mouth and by postings at the University and University
Outpatient Clinic. All subjects who came to our attention were recruited for eligibility
screened and consecutively included if eligible. A total of 114 consecutive subjects
underwent assessment for eligibility (see <xref ref-type="fig" rid="fig1">Fig. 1</xref>
for CONSORT diagram). We included 105 middle-aged (35&#x02013;60 years) healthy Caucasian male and
female subjects without history, signs or symptoms indicative of CVD, including previous
myocardial infarction (MI), stroke and peripheral artery disease or current or previous
medication, and a BMI of 23&#x02013;27 kg/m<sup>2</sup> (inclusion criteria). Exclusion criteria
were manifest or suspected CVD, diabetes, kidney failure, acute inflammation or a heart
rhythm other than sinus, extreme diets including vegetarians and vegans, alcoholism and
vitamin supplement use.<fig id="fig1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>(a) Study flow (CONSORT diagram) and (b) study protocol of the randomised
controlled study. BID, twice daily; FMD, flow-mediated dilation; PWV, pulse wave
velocity; AIX, augmentation index.</p></caption><graphic xlink:href="S0007114515002822_fig1"/></fig>
</p><p>We first performed an open-label kinetic pilot study in five male volunteers. The
subjects received 450 mg of CF twice daily for 1 month to determine the time course of
endothelial function by FMD, which measures endothelial function and is a prospectively
validated surrogate marker of cardiovascular risk.</p><p>Subsequently, we performed a 1-month double-masked, randomised, controlled trial in 100
participants who were randomly (block randomisation) assigned to one of two parallel
groups (1:1 ratio of intervention and controls): either the CF intervention group
(FLAVANOL; 450 mg of total flavanols twice daily) or the CF-free intervention group
(CONTROL; 0 mg of total flavanols twice daily). All interventions were provided as drink
powder in sachets to be freshly prepared by mixing with approximately 500 ml of water.
Drinks were consumed twice a d: one beverage in the morning with breakfast (06.00&#x02013;08.00 h)
and one with the evening meal (18.00&#x02013;20.00 h). We did not require the study subjects to
follow a strict timing. This regimen was maintained for 1 month, with compliance assessed
by the collection of empty sachets on the last study day visit. All measurements were
taken in the fasting state before (&#x02018;baseline&#x02019;) and at 2 h after the first drink on day 1,
and at 1 month (day 28&#x02013;30) again in the fasting state and at 2 h after consumption of the
last drink. Subjects were asked to refrain from consuming excess amounts of flavanol-rich
foods (list provided to participants) for 24 h before study visits. No other restrictions
before and during intervention regarding diet and lifestyle were required. FMD was the
primary end point. Secondary pre-specified end points included office BP and plasma total,
LDL and HDL-cholesterol concentration in order to determine cardiovascular risk parameters
according to the Framingham Risk Prediction model<sup>(</sup>
<xref rid="ref8" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>)</sup>. The 10-year risks to develop CHD or CVD, to experience a MI or stroke or to
die from CHD or CVD were calculated using the Framingham equation in the Excel calculator
(<uri xlink:type="simple" xlink:href="http://cvrisk.mvm.ed.ac.uk/">http://cvrisk.mvm.ed.ac.uk/</uri>). Further pre-specified secondary end points included
parameters derived from pulse wave analysis, including PWV, aortic augmentation index
(AIX), reflective of vascular physicomechanics and central systolic blood pressure (SBP)
and diastolic blood pressure (DBP). A tertiary pre-specified end point was the total
plasma epicatechin metabolite concentration.</p><p>Subjects were asked to follow a 10-min supine rest period before examinations and to
remain in a supine position throughout the examination, including BP measurements, FMD,
pulse wave analysis and blood draws following the identical sequence. FMD was measured on
the right arm, and BP measurements and blood draws were performed on the left arm.</p><p>Participants and investigators were masked throughout the study with regard to flavanol
content of the test drinks, and intervention drinks were allocated in random order using
block randomisation. As the open-label pilot study had only one arm, analyses were
performed in an observer-blinded manner. The ethics committee of the Heinrich-Heine
University approved the study protocol, and all subjects gave written informed consent
(Clinicaltrials.gov: NCT01799005).</p></sec><sec id="sec1-2" sec-type="general"><title>Test materials</title><p>Both interventions used a low-energy fruit-flavoured beverage mix (provided by Mars
Inc.), which was standardised and matched in composition. All beverage mixes were
agglomerated powders with a maltodextrin base into which flavouring and sweeteners were
incorporated. The beverage mixes were provided in sachets (7 g, equals one serving)
labelled with an alphanumeric identifier to enable a double-masked study design. A
high-flavanol cocoa extract (Cocoapro<sup>&#x000ae;</sup>-processed cocoa extract; Mars Inc.) was
the source of flavanols in the CF-containing drink. The CF-containing drink (FLAVANOL)
provided 450 mg of total CF per serving<sup>(</sup>
<xref rid="ref9" ref-type="bibr">
<sup>9</sup>
</xref>
<sup>)</sup>. The total amount of CF in mg represents the sum of all monomeric flavanols
and their oligomers (i.e. procyanidins) with a degree of polymerisation up to and
including 10 (i.e. DP 1&#x02013;10). The predominant monomeric flavanol in this drink was
(&#x02212;)-epicatechin (see <xref ref-type="table" rid="tab1">Table 1</xref>). The control
beverage mix did not contain any cocoa extract, and thus it provided 0 mg of CF (CONTROL).
Given the natural presence of theobromine and caffeine in cocoa extract, both theobromine
and caffeine were added to the control beverage mix in order to match the composition of
alkaloids in the CF-containing test product. Colouring was also added so that the 0 mg CF
CONTROL drink was also indistinguishable in appearance. Compositional details for the 0 mg
(CONTROL) and 450 mg CF (FLAVANOL) test drinks are provided in <xref ref-type="table" rid="tab1">Table 1</xref>.<table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Composition of interventional vehicles ingested bi-daily</p></caption><alternatives><graphic xlink:href="S0007114515002822_tab1"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">FLAVANOL</th><th align="center" rowspan="1" colspan="1">CONTROL</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total cocoa flavanols (mg)</td><td align="char" char="." rowspan="1" colspan="1">450</td><td align="center" rowspan="1" colspan="1">ND</td></tr><tr><td align="left" rowspan="1" colspan="1">Monomers (mg)</td><td align="char" char="." rowspan="1" colspan="1">73</td><td align="center" rowspan="1" colspan="1">ND</td></tr><tr><td align="left" rowspan="1" colspan="1">(&#x02212;)-Epicatechin (mg)</td><td align="char" char="." rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">ND</td></tr><tr><td align="left" rowspan="1" colspan="1">(&#x02212;)-Catechin (mg)</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">ND</td></tr><tr><td align="left" rowspan="1" colspan="1">(+)-Catechin (mg)</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">ND</td></tr><tr><td align="left" rowspan="1" colspan="1">(+)-Epicatechin (mg)</td><td align="center" rowspan="1" colspan="1">ND</td><td align="center" rowspan="1" colspan="1">ND</td></tr><tr><td align="left" rowspan="1" colspan="1">Dimers&#x02013;decamers (mg)</td><td align="char" char="." rowspan="1" colspan="1">377</td><td align="center" rowspan="1" colspan="1">ND</td></tr><tr><td align="left" rowspan="1" colspan="1">Theobromine (mg)</td><td align="char" char="." rowspan="1" colspan="1">44</td><td align="char" char="." rowspan="1" colspan="1">46</td></tr><tr><td align="left" rowspan="1" colspan="1">Caffeine (mg)</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">Fat (mg)</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Carbohydrates (mg)</td><td align="char" char="." rowspan="1" colspan="1">6000</td><td align="char" char="." rowspan="1" colspan="1">6000</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein (mg)</td><td align="char" char="." rowspan="1" colspan="1">100</td><td align="char" char="." rowspan="1" colspan="1">100</td></tr><tr><td align="left" rowspan="1" colspan="1">Energy (kJ)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">104&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">104&#x000b7;6</td></tr><tr><td align="left" rowspan="1" colspan="1">Energy (kcal)</td><td align="char" char="." rowspan="1" colspan="1">25</td><td align="char" char="." rowspan="1" colspan="1">25</td></tr><tr><td align="left" rowspan="1" colspan="1">Na (mg)</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">K (mg)</td><td align="char" char="." rowspan="1" colspan="1">95</td><td align="char" char="." rowspan="1" colspan="1">85</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>ND, not detectable.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec id="sec1-3" sec-type="general"><title>Flow-mediated vasodilation and power analysis of the primary end point</title><p>FMD and nitroglycerin-mediated vasodilation (NMD) were measured in the brachial artery of
the right arm using 5-min forearm occlusion by ultrasound (Vivid I; GE Healthcare) in
combination with a semi-automated analysis system (Brachial Analyzer; MIA), as
described<sup>(</sup>
<xref rid="ref10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup>. The intra- and inter-individual variability for FMD measurements established
in our laboratory are 0&#x000b7;9 % (<sc>sd</sc> of difference between repeated FMD measurements
in twenty middle-aged healthy subjects, unpublished) and 1 % (<sc>sd</sc> within a group
of healthy old subjects)<sup>(</sup>
<xref rid="ref11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>)</sup>. FMD was defined as the primary outcome. On the basis of previous
intervention studies with CF, we expected a change in FMD by 1&#x000b7;3 %<sup>(</sup>
<xref rid="ref4" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>)</sup>. Assuming an <sc>sd</sc> of change in FMD of 1 %, fifty experimental and
fifty control subjects would provide sufficient power to detect an absolute change in FMD
of 0&#x000b7;6 % (two-sided &#x003b1; of 5 %, power=0&#x000b7;80). As we were planning on recruiting 50 % women,
we also kept the possibility in mind that women may respond differently from men.
Therefore, it should be mentioned that under the same conditions twenty-five experimental
and twenty-five control subjects would provide sufficient power to detect an absolute
change in FMD of 0&#x000b7;8 % (two-sided &#x003b1; of 5 %, power=0&#x000b7;80)<sup>(</sup>
<xref rid="ref12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>)</sup>.</p></sec><sec id="sec1-4" sec-type="general"><title>Blood pressure measurements</title><p>Office BP was measured using an automated clinical digital sphygmomanometer (Dynamap) at
the upper left arm in supine position, after 10 min of rest in a quiet room with the arm
at the heart level. We took three measurements, discarded the first and averaged the
second and third for further analysis. Central BP was derived from peripheral pulse wave
analysis (SphygmoCor<sup>&#x000ae;</sup>; AtCor-Medical).</p></sec><sec id="sec1-5" sec-type="general"><title>Cholesterol and clinical chemistry measurements</title><p>All clinical chemistry parameters including total, LDL and HDL-cholesterol, TAG
(enzymatic photometric assay; Roche Diagnostics), Hb<sub>A1c</sub>, C-reactive protein
(quantitative immunoturbidimetric assay; Roche Diagnostics), glucose (hexokinase assay)
and whole blood count (flow cytometry; Sysmex) were measured from yellow and purple top
serum vacutainer tubes using standard techniques by the Institute for Clinical Chemistry,
University Duesseldorf, Germany.</p></sec><sec id="sec1-6" sec-type="general"><title>Pulse wave analysis</title><p>Central BP parameters including AIX and PWV were measured in supine subjects by
applanation tonometry using the SphygmoCor<sup>&#x000ae;</sup> system. By means of a transfer
function, the pressure waveform of the ascending aorta was synthesised. PWV was determined
from measurements taken at the carotid and femoral artery, as previously described<sup>(</sup>
<xref rid="ref13" ref-type="bibr">
<sup>13</sup>
</xref>
<sup>)</sup>.</p></sec><sec id="sec1-7" sec-type="general"><title>Estimation of background flavanol intake</title><p>Background flavanol intake was assessed using a modified version of the EPIC
Norfolk<sup>(</sup>
<xref rid="ref14" ref-type="bibr">
<sup>14</sup>
</xref>
<sup>)</sup> FFQ. Flavanol monomer, epicatechin and CF intakes were calculated using the
Flaviola Flavanol Food Composition Database<sup>(</sup>
<xref rid="ref15" ref-type="bibr">
<sup>15</sup>
</xref>
<sup>)</sup>.</p></sec><sec id="sec1-8" sec-type="general"><title>Analysis of flavanols and their metabolites in plasma</title><p>(&#x02212;)-Epicatechin and its related metabolites were analysed in plasma by HPLC-FLD/UV and
electrochemical detection using authentic standards provided by Mars Inc., as previously
described<sup>(</sup>
<xref rid="ref16" ref-type="bibr">
<sup>16</sup>
</xref>
<sup>)</sup>. Before analysis, plasma samples (0&#x000b7;5 ml) were defrosted on ice and then
subjected to <italic>&#x003b2;</italic>-glucuronidase and sulfatase treatment (2000 U/ml; 40 min;
37&#x000b0;C). Then, samples were mixed with 2 ml of acidified ice-cold methanol (0&#x000b7;5 % acetic
acid in methanol, v/v) containing 3&#x02032;-<italic>O</italic>-ethyl-(&#x02212;)-epicatechin (500
n<sc>m</sc>) as a recovery standard. Samples were centrifuged at 17 000 <italic><bold>g</bold></italic> for 15 min at 4&#x000b0;C and the supernatant was collected. The pellet was extracted
again with 2 ml of acidified ice-cold methanol (0&#x000b7;5 % acetic acid in methanol, v/v)
containing 3&#x02032;-<italic>O</italic>-ethyl-(&#x02212;)-epicatechin (500 n<sc>m</sc>), and then with 1
ml of 50 % methanol acidified with 0&#x000b7;5 % acetic acid and containing
3&#x02032;-<italic>O</italic>-ethyl-(&#x02212;)-epicatechin (500 n<sc>m</sc>). Combined supernatants
underwent concentration (to approximately 50 &#x000b5;l) using a Speedvac system (Thermo Fisher
Scientific Inc.) and were mixed with resorcinol (300 pmol) and catechol (300 pmol) before
analysis by HPLC. Flavanol monomers and <italic>O</italic>-methylated metabolites were
analysed using a Hewlett-Packard 1200 series HPLC (Hewlett-Packard) equipped with diode
array and fluorescent detection. Samples (50 &#x000b5;l) were injected onto a reversed-phase
Phenomenex Luna C18(2) column (4&#x000b7;6&#x000d7;150 mm) with 3-&#x000b5;m particle size. The mobile phase
consisted of (A) HPLC-grade water, (B) 200 m<sc>m</sc> Na acetate, pH 4&#x000b7;4/methanol (84/16)
and (C) acetonitrile, and the following gradient protocol was run: 0 min, 75 % A, 25 % B;
5 min, 75 % A, 25 % B; 20 min, 65 % A, 25 % B; 28 min, 63 % A, 25 % B; 34 min, 55 % A; 25
% B; 41 min, 45 % A, 25 % B; 45 min, 25 % B, 75 % C; 55 min, 25 % B, 75 % C; 56&#x000b7;1 min 75 %
A, 25 % B; 60 min, 75 % A, 25 % B. The flow rate was 0&#x000b7;8 ml/min. Detection of flavanols
and their metabolites was performed using a fluorescent detector with an excitation
wavelength of 276 nm and an emission wavelength of 316 nm. The concentration of each
compound was determined using an external calibration curve produced with the use of
authentic standards.</p></sec><sec id="sec1-9" sec-type="general"><title>Statistical methods</title><p>The characteristics of the study population are expressed as mean values and standard
deviations. Changes in FMD values in the pilot study were compared by one-way
repeated-measures ANOVA and are presented as mean values and their standard error of
means. The primary test for an effect in the RCT was an independent <italic>t</italic>
test comparing the difference between changes due to FLAVANOL and CONTROL at 1 month. Mean
values of results are presented as mean values and their standard error of means, and
differences between responses are presented as mean values and 95 % confidence intervals.
Responses to treatments were calculated as changes in respective parameters (e.g. FMD):
1-month values minus baseline values on day 1. We also evaluated the difference between
changes at 2 h after acute consumption of intervention drinks on day 1 and at 1 month as
compared with baseline on day 1. Data not normally distributed are presented as median
(interquartile range), and group differences are compared with Mann&#x02013;Whitney
<italic>U</italic> tests. Analyses were computed with SPSS 20 (IBM). Correlations were
presented as Pearson&#x02019;s <italic>r</italic>.</p></sec></sec><sec sec-type="general" id="sec2"><title>Results</title><sec id="sec2-1" sec-type="general"><title>Baseline characteristics of the healthy study population</title><p>None of the 105 subjects had been previously diagnosed with or had clinical signs or
symptoms of CVD. None of the participants were on current medical treatment, including
medication, and the baseline demographic parameters were within normal limits (<xref ref-type="table" rid="tab2">Table 2</xref>). There were no statistically significant
differences between the CONTROL and FLAVANOL group with regard to these parameters.
Furthermore, our analysis of FFQ showed that the estimated intake of flavanols was low,
comparable to the general European public<sup>(</sup>
<xref rid="ref15" ref-type="bibr">
<sup>15</sup>
</xref>
<sup>)</sup>, and there was no difference between the groups. On the basis of their
Framingham Risk Scores, the participants exhibited a low risk &#x02013; that is, the 10-year risk
to be diagnosed with CHD or to experience a MI was 3&#x000b7;4 (<sc>sd</sc> 3&#x000b7;7) % and 1&#x000b7;3
(<sc>sd</sc> 2&#x000b7;1) %, respectively (<italic>n</italic> 105). The estimated risk to die from
CVD over the next 10 years was 0&#x000b7;5 (<sc>sd</sc> 0&#x000b7;9) %.<table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Baseline characteristics of study groups (Mean values and standard deviations)</p></caption><alternatives><graphic xlink:href="S0007114515002822_tab2"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="2">FLAVANOL</th><th align="center" rowspan="1" colspan="2">CONTROL</th><th align="center" rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sd</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sd</sc>
</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic>*</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="center" rowspan="1" colspan="2">55</td><td align="center" rowspan="1" colspan="2">50</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Male/female</td><td align="center" rowspan="1" colspan="2">30/25</td><td align="center" rowspan="1" colspan="2">25/25</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="char" char="." rowspan="1" colspan="1">45</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">44</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;778</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="char" char="." rowspan="1" colspan="1">25</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">26</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;310</td></tr><tr><td align="left" rowspan="1" colspan="1">Height (cm)</td><td align="char" char="." rowspan="1" colspan="1">180</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">178</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;453</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="char" char="." rowspan="1" colspan="1">83</td><td align="char" char="." rowspan="1" colspan="1">14</td><td align="char" char="." rowspan="1" colspan="1">82</td><td align="char" char="." rowspan="1" colspan="1">14</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;579</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (&#x003bc;mol/l)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">71</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">80</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">18</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;991</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol (mmol/l)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;564</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL-cholesterol (mmol/l)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;0</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;315</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-cholesterol (mmol/l)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;900</td></tr><tr><td align="left" rowspan="1" colspan="1">TAG (mmol/l)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;104</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting plasma glucose (mmol/l)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">5&#x000b7;0</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;727</td></tr><tr><td align="left" rowspan="1" colspan="1">Hb<sub>A1c</sub> (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">5&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">5&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;649</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP (mmHg)</td><td align="char" char="." rowspan="1" colspan="1">126</td><td align="char" char="." rowspan="1" colspan="1">14</td><td align="char" char="." rowspan="1" colspan="1">127</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;546</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP (mmHg)</td><td align="char" char="." rowspan="1" colspan="1">80</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">79</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;811</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart rate (bpm)</td><td align="char" char="." rowspan="1" colspan="1">64</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">64</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;908</td></tr><tr><td align="left" rowspan="1" colspan="1">CRP (mmol/l)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;692</td></tr><tr><td align="left" rowspan="1" colspan="1">Hb (mg/l)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">143</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">13</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">140</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">20</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;721</td></tr><tr><td align="left" rowspan="1" colspan="1">Leucocytes (1000/ml)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">5&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">5&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;489</td></tr><tr><td align="left" rowspan="1" colspan="1">Flavanol monomer intake (mg/d)&#x02020;</td><td align="char" char="." rowspan="1" colspan="1">35</td><td align="char" char="." rowspan="1" colspan="1">43</td><td align="char" char="." rowspan="1" colspan="1">32</td><td align="char" char="." rowspan="1" colspan="1">45</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;926</td></tr><tr><td align="left" rowspan="1" colspan="1">Epicatechin intake (mg/d)&#x02020;</td><td align="char" char="." rowspan="1" colspan="1">11</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;781</td></tr><tr><td align="left" rowspan="1" colspan="1">Cocoa flavanol intake (mg/d)&#x02020;</td><td align="char" char="." rowspan="1" colspan="1">106</td><td align="char" char="." rowspan="1" colspan="1">85</td><td align="char" char="." rowspan="1" colspan="1">106</td><td align="char" char="." rowspan="1" colspan="1">82</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;701</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>CRP, C-reactive protein; DBP, office diastolic blood pressure; SBP, office
systolic blood pressure.</p><p>* <italic>P</italic> value from the unpaired <italic>t</italic> test.</p><p>&#x02020; Values are medians and interquartile ranges and were analysed using the
Mann&#x02013;Whitney <italic>U</italic> test.</p></fn></table-wrap-foot></table-wrap>
</p><p>The first five subjects recruited were male, and they participated in the open-label
pilot study to (a) verify the efficacy of the flavanol drink to increase FMD, (b) allow
re-assessment of effect size to power the main study and gain insight into (c) temporal
responses and timing of the main study (<xref ref-type="fig" rid="fig2">Fig. 2</xref>).
The remaining 100 subjects were included in the main study and randomly assigned to either
FLAVANOL or CONTROL treatment. The test drinks were well tolerated and not a single
adverse event was reported.<fig id="fig2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Time course of flow-mediated dilation (FMD) during the open-label pilot study.
Measurements were taken before (0 h) and at 0, 1 and 2 h after ingestion of the
first intervention drink on days 1, 7, 14, 21 and 28 while consuming the drink twice
per d (<italic>n</italic> 5). Ingestion of a single test drink led to an &#x02018;acute&#x02019;
increase in FMD on days 1 and 7 (A). Although the FMD value as measured after
repeated consumption of the drink increased the &#x02018;chronic effect&#x02019; (B),
&#x02018;acute-on-chronic&#x02019; improvements were no longer statistically significant at days 14,
21 and 28 during daily consumption (C). * <italic>P</italic>&#x0003c;0&#x000b7;05
<italic>v</italic>. 0 h at the same day, respectively, &#x02020;
<italic>P</italic>&#x0003c;0&#x000b7;05 <italic>v</italic>. 0 h at day 1. Values are means
with their standard errors represented by vertical bars.</p></caption><graphic xlink:href="S0007114515002822_fig2"/></fig>
</p></sec><sec id="sec2-2" sec-type="general"><title>Time course of FMD during daily open-label FLAVANOL consumption over 1 month</title><p>We first performed an open-label pilot study in five male volunteers, who received 450 mg
of CF twice daily for 1 month to determine the time course of FMD, the primary end point
of the main randomised controlled study. FMD measurements were taken in the fasting state
before (0 h) and at 1 and 2 h after consumption of the first drink in the morning on days
1, 7, 14, 21 and 28.</p><p>As depicted in <xref ref-type="fig" rid="fig2">Fig. 2</xref>, the time course identified
an &#x02018;acute&#x02019; increase in FMD at 1 and 2 h after consumption of CF and a &#x02018;chronic&#x02019; increase
in fasting FMD. With bi-daily CF consumption over weeks, the FMD as measured after
overnight fasting (&#x0003e;12 h after consumption of last intervention drink) increased
from day 1 (6&#x000b7;0 (<sc>sem</sc> 0&#x000b7;3) %) to day 7 (6&#x000b7;6 (<sc>sem</sc> 0&#x000b7;2) %) and again from
day 7 to day 14 (7&#x000b7;8 (<sc>sem</sc> 0&#x000b7;1) %). At days 21 and 28, we observed no further
increase in the fasting FMD and acute ingestion, suggesting a saturation of CF-related
&#x02018;chronic&#x02019; effects (day 21: 8&#x000b7;2 (<sc>sem</sc> 0&#x000b7;2) %, day 28: 8&#x000b7;2 (<sc>sem</sc> 0&#x000b7;2) %).
The change in fasting FMD between day 1 and day 28 was 2&#x000b7;3 (<sc>sd</sc> 0&#x000b7;4) %. Although
fasting FMD &#x02018;chronically&#x02019; increased, additional &#x02018;acute&#x02019; CF consumption only significantly
improved FMD at days 1 and 7.</p></sec><sec id="sec2-3" sec-type="general"><title>Flavanol intake improves endothelial function</title><p>In the 1-month randomised controlled trial, FLAVANOL consumption led to a significant
improvement in FMD as compared with CONTROL (<xref ref-type="table" rid="tab3">Table
3</xref>). FMD improved by 0&#x000b7;7 % (95 % CI 0&#x000b7;5, 0&#x000b7;9 %) at 2 h and by 1&#x000b7;2 % (95 % CI 1&#x000b7;0,
1&#x000b7;4 %) at 1 month. There were no differences in baseline FMD between men (5&#x000b7;3
(<sc>sem</sc> 0&#x000b7;1) %) and women (5&#x000b7;3 (<sc>sem</sc> 0&#x000b7;1) %, <italic>P</italic>=0&#x000b7;764
<italic>t</italic> test). The baseline diameter of the brachial artery and NMD remained
unaffected by either FLAVANOL or CONTROL.<table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Overview of primary, secondary and tertiary end points (Mean values with their
standard errors; 95 % confidence intervals)</p></caption><alternatives><graphic xlink:href="S0007114515002822_tab3"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="8">FLAVANOL (<italic>n</italic>&#x000b7;50)</th><th align="center" rowspan="1" colspan="8">CONTROL (<italic>n</italic>&#x000b7;50)</th><th align="center" rowspan="1" colspan="6"/></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="2">Baseline</th><th align="center" rowspan="1" colspan="2">2 h</th><th align="center" rowspan="1" colspan="2">1 month</th><th align="center" rowspan="1" colspan="2">1 month, 2 h</th><th align="center" rowspan="1" colspan="2">Baseline</th><th align="center" rowspan="1" colspan="2">2 h</th><th align="center" rowspan="1" colspan="2">1 month</th><th align="center" rowspan="1" colspan="2">1 month, 2 h</th><th align="center" rowspan="1" colspan="1">Difference</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Difference</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Difference at</th><th align="center" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</td><td align="center" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</td><td align="center" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</td><td align="center" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</td><td align="center" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</td><td align="center" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</td><td align="center" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</td><td align="center" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</td><td align="center" rowspan="1" colspan="1"> at 2 h*</td><td align="center" rowspan="1" colspan="1">95 % CI</td><td align="center" rowspan="1" colspan="1">at 1 month*</td><td align="center" rowspan="1" colspan="1">95 % CI</td><td align="center" rowspan="1" colspan="1">1 month, 2 h*</td><td align="center" rowspan="1" colspan="1">95 % CI</td></tr><tr><td align="left" rowspan="1" colspan="1">Primary end point (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">FMD</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">5&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">6&#x000b7;0</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">6&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">6&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">5&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">5&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">5&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">5&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;7</td><td align="char" char="," rowspan="1" colspan="1">0&#x000b7;5, 0&#x000b7;9&#x02020;</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;2</td><td align="char" char="," rowspan="1" colspan="1">1&#x000b7;0, 1&#x000b7;4&#x02020;</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;6</td><td align="char" char="," rowspan="1" colspan="1">1&#x000b7;3, 1&#x000b7;8&#x02020;</td></tr><tr><td align="left" rowspan="1" colspan="1">Secondary end points (mmHg)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Office SBP</td><td align="center" char="." rowspan="1" colspan="1">126</td><td align="center" char="." rowspan="1" colspan="1">2</td><td align="center" char="." rowspan="1" colspan="1">124</td><td align="center" char="." rowspan="1" colspan="1">2</td><td align="center" char="." rowspan="1" colspan="1">121</td><td align="center" char="." rowspan="1" colspan="1">2</td><td align="center" char="." rowspan="1" colspan="1">121</td><td align="center" char="." rowspan="1" colspan="1">2</td><td align="center" char="." rowspan="1" colspan="1">127</td><td align="center" char="." rowspan="1" colspan="1">1</td><td align="center" char="." rowspan="1" colspan="1">127</td><td align="center" char="." rowspan="1" colspan="1">2</td><td align="center" char="." rowspan="1" colspan="1">126</td><td align="center" char="." rowspan="1" colspan="1">2</td><td align="center" char="." rowspan="1" colspan="1">125</td><td align="center" char="." rowspan="1" colspan="1">2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;1&#x000b7;8</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;4&#x000b7;9, 1&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;4&#x000b7;4</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;7&#x000b7;9, &#x02212;0&#x000b7;9&#x02020;</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;4&#x000b7;6</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;7&#x000b7;1, &#x02212;0&#x000b7;1&#x02020;</td></tr><tr><td align="left" rowspan="1" colspan="1">Office DBP</td><td align="center" char="." rowspan="1" colspan="1">79</td><td align="center" char="." rowspan="1" colspan="1">1</td><td align="center" char="." rowspan="1" colspan="1">77</td><td align="center" char="." rowspan="1" colspan="1">1</td><td align="center" char="." rowspan="1" colspan="1">75</td><td align="center" char="." rowspan="1" colspan="1">1</td><td align="center" char="." rowspan="1" colspan="1">76</td><td align="center" char="." rowspan="1" colspan="1">1</td><td align="center" char="." rowspan="1" colspan="1">78</td><td align="center" char="." rowspan="1" colspan="1">1</td><td align="center" char="." rowspan="1" colspan="1">78</td><td align="center" char="." rowspan="1" colspan="1">1</td><td align="center" char="." rowspan="1" colspan="1">78</td><td align="center" char="." rowspan="1" colspan="1">1</td><td align="center" char="." rowspan="1" colspan="1">79</td><td align="center" char="." rowspan="1" colspan="1">1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;2&#x000b7;4</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;5&#x000b7;1, 0&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;3&#x000b7;9</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;6&#x000b7;7, &#x02212;1&#x000b7;1&#x02020;</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;3&#x000b7;8</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;6&#x000b7;2, &#x02212;1&#x000b7;3&#x02020;</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol (mmol/l)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;84</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;13</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;64</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;13</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;79</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;13</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;77</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;10</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;0&#x000b7;20</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;0&#x000b7;39, &#x02212;0&#x000b7;01&#x02020;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">LDL-cholesterol (mmol/l)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;08</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;13</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;90</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;13</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;11</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;13</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;11</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;10</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;0&#x000b7;17</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;0&#x000b7;32, &#x02212;0&#x000b7;02&#x02020;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">HDL-cholesterol (mmol/l)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;53</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;05</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;61</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;05</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;50</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;05</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;48</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;05</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;10</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;0&#x000b7;04, 0&#x000b7;17&#x02020;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">PWV (m/s)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">7&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">6&#x000b7;9</td><td align="left" rowspan="1" colspan="1">0&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">6&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">6&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">7&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">7&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">7&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">7&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;0&#x000b7;3</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;0&#x000b7;6, &#x02212;0&#x000b7;1&#x02020;</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;0&#x000b7;4</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;0&#x000b7;8, &#x02212;0&#x000b7;04&#x02020;</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;0&#x000b7;4</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;0&#x000b7;7, &#x02212;0&#x000b7;005&#x02020;</td></tr><tr><td align="left" rowspan="1" colspan="1">AIX (%)</td><td align="center" char="." rowspan="1" colspan="1">17</td><td align="center" char="." rowspan="1" colspan="1">2</td><td align="center" char="." rowspan="1" colspan="1">14</td><td align="center" char="." rowspan="1" colspan="1">2</td><td align="center" char="." rowspan="1" colspan="1">12</td><td align="center" char="." rowspan="1" colspan="1">2</td><td align="center" char="." rowspan="1" colspan="1">10</td><td align="center" char="." rowspan="1" colspan="1">2</td><td align="center" char="." rowspan="1" colspan="1">15</td><td align="center" char="." rowspan="1" colspan="1">2</td><td align="center" char="." rowspan="1" colspan="1">15</td><td align="center" char="." rowspan="1" colspan="1">2</td><td align="center" char="." rowspan="1" colspan="1">15</td><td align="center" char="." rowspan="1" colspan="1">2</td><td align="center" char="." rowspan="1" colspan="1">14</td><td align="center" char="." rowspan="1" colspan="1">2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;3&#x000b7;3</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;6&#x000b7;4, &#x02212;0&#x000b7;3&#x02020;</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;5&#x000b7;3</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;8&#x000b7;9, &#x02212;1&#x000b7;6&#x02020;</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;5&#x000b7;9</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;9&#x000b7;5, &#x02212;2&#x000b7;3&#x02020;</td></tr><tr><td align="left" rowspan="1" colspan="1">Central SBP (mmHg)</td><td align="center" char="." rowspan="1" colspan="1">118</td><td align="center" char="." rowspan="1" colspan="1">2</td><td align="center" char="." rowspan="1" colspan="1">115</td><td align="center" char="." rowspan="1" colspan="1">2</td><td align="center" char="." rowspan="1" colspan="1">112</td><td align="center" char="." rowspan="1" colspan="1">2</td><td align="center" char="." rowspan="1" colspan="1">113</td><td align="center" char="." rowspan="1" colspan="1">2</td><td align="center" char="." rowspan="1" colspan="1">116</td><td align="center" char="." rowspan="1" colspan="1">2</td><td align="center" char="." rowspan="1" colspan="1">117</td><td align="center" char="." rowspan="1" colspan="1">2</td><td align="center" char="." rowspan="1" colspan="1">116</td><td align="center" char="." rowspan="1" colspan="1">2</td><td align="center" char="." rowspan="1" colspan="1">115</td><td align="center" char="." rowspan="1" colspan="1">2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;2&#x000b7;8</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;5&#x000b7;5, &#x02212;0&#x000b7;2&#x02020;</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;5&#x000b7;3</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;8&#x000b7;5, &#x02212;2&#x000b7;1&#x02020;</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;3&#x000b7;8</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;6&#x000b7;8, &#x02212;0&#x000b7;7&#x02020;</td></tr><tr><td align="left" rowspan="1" colspan="1">Central DBP (mmHg)</td><td align="center" char="." rowspan="1" colspan="1">80</td><td align="center" char="." rowspan="1" colspan="1">1</td><td align="center" char="." rowspan="1" colspan="1">78</td><td align="center" char="." rowspan="1" colspan="1">1</td><td align="center" char="." rowspan="1" colspan="1">76</td><td align="center" char="." rowspan="1" colspan="1">1</td><td align="center" char="." rowspan="1" colspan="1">76</td><td align="center" char="." rowspan="1" colspan="1">1</td><td align="center" char="." rowspan="1" colspan="1">79</td><td align="center" char="." rowspan="1" colspan="1">1</td><td align="center" char="." rowspan="1" colspan="1">79</td><td align="center" char="." rowspan="1" colspan="1">1</td><td align="center" char="." rowspan="1" colspan="1">79</td><td align="center" char="." rowspan="1" colspan="1">1</td><td align="center" char="." rowspan="1" colspan="1">79</td><td align="center" char="." rowspan="1" colspan="1">1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;2&#x000b7;5</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;4&#x000b7;8, &#x02212;0&#x000b7;8&#x02020;</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;4&#x000b7;7</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;7&#x000b7;8, &#x02212;1&#x000b7;7&#x02020;</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;4&#x000b7;4</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;7&#x000b7;1, &#x02212;1&#x000b7;7&#x02020;</td></tr><tr><td align="left" rowspan="1" colspan="1">10-year CHD risk (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;4</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;0&#x000b7;6</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;1&#x000b7;3, &#x02212;0&#x000b7;3&#x02020;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">10-year MI risk (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;3</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;2</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;3</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;3</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;0&#x000b7;5</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;0&#x000b7;8, &#x02212;1&#x000b7;2&#x02020;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">10-year stroke risk (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;0&#x000b7;1</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;0&#x000b7;2, 0&#x000b7;03&#x02020;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">10-year CVD risk (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;7</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;7</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;7</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;1&#x000b7;0</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;1&#x000b7;7, &#x02212;0&#x000b7;4&#x02020;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">10-year CHD death risk (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;0&#x000b7;2</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;0&#x000b7;3, &#x02212;0&#x000b7;004&#x02020;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">10-year CVD death risk (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">&#x02212;0&#x000b7;2</td><td align="char" char="," rowspan="1" colspan="1">&#x02212;0&#x000b7;3, &#x02212;0&#x000b7;03&#x02020;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Tertiary end point (nmol/l)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Epicatechin metabolites</td><td align="center" char="." rowspan="1" colspan="1">4</td><td align="center" char="." rowspan="1" colspan="1">3</td><td align="center" char="." rowspan="1" colspan="1">991</td><td align="center" char="." rowspan="1" colspan="1">64</td><td align="center" char="." rowspan="1" colspan="1">71</td><td align="center" char="." rowspan="1" colspan="1">26</td><td align="center" char="." rowspan="1" colspan="1">1049</td><td align="center" char="." rowspan="1" colspan="1">76</td><td align="center" char="." rowspan="1" colspan="1">0<xref ref-type="fn" rid="tab3fn1">&#x02021;</xref>
</td><td align="center" char="." rowspan="1" colspan="1">0</td><td align="center" char="." rowspan="1" colspan="1">0<xref ref-type="fn" rid="tab3fn1">&#x02021;</xref>
</td><td align="center" char="." rowspan="1" colspan="1">0</td><td align="center" char="." rowspan="1" colspan="1">0<xref ref-type="fn" rid="tab3fn1">&#x02021;</xref>
</td><td align="center" char="." rowspan="1" colspan="1">0</td><td align="center" char="." rowspan="1" colspan="1">0<xref ref-type="fn" rid="tab3fn1">&#x02021;</xref>
</td><td align="center" char="." rowspan="1" colspan="1">0</td><td align="center" char="." rowspan="1" colspan="1">987</td><td align="center" char="." rowspan="1" colspan="1">857, 1118&#x02020;</td><td align="center" char="." rowspan="1" colspan="1">68</td><td align="center" char="." rowspan="1" colspan="1">10, 125&#x02020;</td><td align="center" char="." rowspan="1" colspan="1">1045</td><td align="center" char="." rowspan="1" colspan="1">890, 1200&#x02020;</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>AIX, augmentation index; DBP, diastolic blood pressure; FMD, flow-mediated
dilation; MI, myocardial infarction; PWV, pulse wave velocity; SBP, systolic blood
pressure.</p><p>* Differences with CI are from the unpaired <italic>t</italic> test comparing
FLAVANOL with CONTROL changes from baseline.</p><p>&#x02020; 95 % CI does not span zero, indicating significant difference.</p></fn><fn id="tab3fn1"><label>&#x02021;</label><p>Below limit of detection.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec id="sec2-4" sec-type="general"><title>Flavanol intake lowers blood pressure and decreases vascular stiffness</title><p>The consumption of FLAVANOL over 1 month led to a significant decrease in office SBP by
4&#x000b7;4 mmHg (95 % CI 0&#x000b7;9, 7&#x000b7;9 mmHg) and office DBP by 3&#x000b7;9 mmHg (95 % CI 1&#x000b7;1, 6&#x000b7;7 mmHg) as
compared with CONTROL (<xref ref-type="table" rid="tab3">Table 3</xref>). Pulse wave
analysis showed that central SBP and DBP responses were similar to peripheral BP results
with significant lowering by 4&#x000b7;3 mmHg (95 % CI 7&#x000b7;6, 0&#x000b7;8 mmHg) and 4&#x000b7;7 mmHg (95 % CI 1&#x000b7;7,
7&#x000b7;8 mmHg), respectively. PWV and AIX decreased by 0&#x000b7;4 m/s (95 % CI 0&#x000b7;8, 0&#x000b7;04 m/s) and 5&#x000b7;3
% (95 % CI 2&#x000b7;1, 8&#x000b7;5 %) at 1 month of FLAVANOL as compared with CONTROL. No changes in body
weight were observed.</p></sec><sec id="sec2-5" sec-type="general"><title>Flavanol intake decreases total and LDL-cholesterol, but increases HDL-cholesterol</title><p>Both total and LDL-cholesterol significantly decreased by 0&#x000b7;20 mmol/l (95 % CI 0&#x000b7;39, 0&#x000b7;01
mmol/l) and 0&#x000b7;17 mmol/l (95 % CI 0&#x000b7;32, 0&#x000b7;02 mmol/l), whereas HDL-cholesterol increased by
0&#x000b7;10 mmol/l (95 % CI 0&#x000b7;04, 0&#x000b7;17 mmol/l) at 1 month after FLAVANOL as compared with
CONTROL. No significant changes were observed with regard to TAG, fasting plasma glucose
or Hb<sub>A1c</sub>.</p></sec><sec id="sec2-6" sec-type="general"><title>Plasma levels of structurally related flavanol metabolites</title><p>At the baseline visit (day 1, 0 h), the fasting levels of total plasma flavanols were
below the limit of detection in ninety-eight subjects. At 2 h after acute consumption of
FLAVANOL, the concentration of structurally related flavanol metabolites significantly
increased in plasma (987 nmol/l (95 % CI 857, 1118 nmol/l)) over CONTROL. After 1 month of
twice-daily CF consumption and following overnight fasting, fasting levels were again in
all but seven below the limit of detection. Additional acute ingestion of FLAVANOL in
contrast to CONTROL led to flavanol plasma concentration increase of 1045 nmol/l (95 % CI
890, 1200 nmol/l), but these levels were not significantly different from values observed
after acute ingestion on day 1 (<italic>t</italic> test). Whereas &#x02018;acute&#x02019; changes in FMD
could be directly related to bioactive flavanol metabolites, &#x02018;chronic&#x02019; changes in FMD as
measured after overnight fasting are difficult to directly relate to plasma flavanols, as
there were basically no plasma flavanols detectable in the subjects at this time point.
The mechanism underlying the effects may be related as judged by the fact that there is no
acute effect once a chronic effect is established after more than 2 weeks of chronic
consumption but are probably different in nature as they persist after overnight fasting.
However, we observed a significant correlation between an increase in FMD and increase in
plasma flavanols at 2 h post consumption (<italic>r</italic> 0&#x000b7;44,
<italic>P</italic>&#x0003c;0&#x000b7;0001) and also a significant correlation between &#x02018;chronic&#x02019; FMD
improvements at 1 month and the acute increase in plasma flavanols at 2 h as an index of
individual flavanol bioavailability (<italic>r</italic> 0&#x000b7;67,
<italic>P</italic>&#x0003c;0&#x000b7;0001).</p></sec><sec id="sec2-7" sec-type="general"><title>Initial assessments of the impact of flavanol intake on CVD risk using Framingham
Risk Scores</title><p>As described above, the study participants were healthy and at low cardiovascular risk
based on their Framingham Risk Scores. To evaluate the primary preventive potential of
flavanols, we calculated changes in components of the Framingham Risk Score using the age,
the total and HDL-cholesterol and office SBP values (absolute changes are given in <xref ref-type="table" rid="tab3">Table 3</xref>). FLAVANOL led to significant decreases in
the estimated 10-year risk to be diagnosed with CHD (percent decrease relative to
baseline: 21 % (95 % CI 8, 33 %)) or CVD (percent decrease: 22 % (95 % CI 8, 36 %)) or
experience MI (percent decrease: 31 % (95 % CI 9, 51 %)). The decrease in stroke risk was
not statistically significant. The predicted 10-year risk to die from CHD or CVD was
lowered (percent decrease: 37 % (95 % CI 17, 56 %) and 30 % (95 % CI 10, 49 %)) by
FLAVANOL over CONTROL.</p></sec></sec><sec sec-type="general" id="sec3"><title>Discussion</title><sec id="sec3-1" sec-type="general"><title>Study design and effect size of <italic>cocoa flavanol</italic>-induced changes on
vascular function</title><p>The Flaviola Health study is the first randomised controlled trial to establish the
efficacy of CF for improvement of established parameters of vascular function in healthy
middle-aged individuals. Several features of this study are distinctive in testing the
concept that dietary CF intake can maintain vascular health: (1) the study cohort
consisted of healthy individuals without any history, signs or symptoms of CVD, and it is
representative for a middle-aged European population with regard to both general health
status and habitual average flavanol intake<sup>(</sup>
<xref rid="ref15" ref-type="bibr">
<sup>15</sup>
</xref>
<sup>)</sup>; (2) vascular function was comprehensively assessed at the level of conduit
and resistance arteries, including acute and long-term effects, allowing for a
comprehensive characterisation of circulatory function; (3) the study was undertaken using
a randomised, double-masked design, and based on the use of nutrient-matched and
standardised CF-rich and CF-free drinks, allowing for the mitigation of potentially
confounding effects mediated by other bioactive food components; (4) a preceding
open-label run-in study permitted reliable re-assessment of effect size and time course,
enabling power analysis and final design for the main Flaviola Health study; and (5)
changes in vascular function were measured along with established surrogates of
cardiovascular risk, such as BP and cholesterol, allowing the assessment of changes in
individual cardiovascular risk scores<sup>(</sup>
<xref rid="ref7" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>,</sup>
<xref rid="ref17" ref-type="bibr">
<sup>17</sup>
</xref>
<sup>)</sup>. Taken together, this approach enabled us to test the hypothesis of whether
or not CF intake improves vascular function even in healthy individuals. In addition, we
aimed at assessing the effects of CF in the context of the maintenance of vascular health
&#x02013; a concept that gained renewed attention through recent publications by the American
Heart Association<sup>(</sup>
<xref rid="ref18" ref-type="bibr">
<sup>18</sup>
</xref>
<sup>)</sup> and others &#x02013; and at evaluating the potential of CF in primary CVD prevention
and public health.</p><p>The primary end point of the study was FMD. FMD is a validated prognostic marker of
cardiovascular risk, and an improvement in 1 % FMD has been associated with a decrease in
overall CVD risk over 3&#x000b7;6 years of 8 %<sup>(</sup>
<xref rid="ref19" ref-type="bibr">
<sup>19</sup>
</xref>
<sup>)</sup>. In the present study, in which we assessed FMD after overnight fast, we
observed a significant increase in FMD of 1&#x000b7;2 % after 1 month of daily CF consumption.
Although the 1-month duration of this study represents one of its limitations, this time
frame of assessing changes in FMD is regarded as clinically relevant<sup>(</sup>
<xref rid="ref7" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup>, according to the recent EFSA consensus statement on the scientific
requirements for studies aiming at supporting FMD-based health claims<sup>(</sup>
<xref rid="ref7" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup>. Together with the fact that this study is the first larger-scale flavanol
dietary intervention to investigate healthy populations, we would advance that our data
are pertinent and meaningful. Generally considering the effect size in the context of
previous interventions with FMD as the primary end point, which do not thus far include
longer-term studies in healthy individuals, similar degrees of improvement have been
reported for some, but not all, interventions in patients<sup>(</sup>
<xref rid="ref20" ref-type="bibr">
<sup>20</sup>
</xref>
<sup>)</sup>, including the use of ACE inhibitors<sup>(</sup>
<xref rid="ref21" ref-type="bibr">
<sup>21</sup>
</xref>
<sup>)</sup>, statins<sup>(</sup>
<xref rid="ref20" ref-type="bibr">
<sup>20</sup>
</xref>
<sup>,</sup>
<xref rid="ref22" ref-type="bibr">
<sup>22</sup>
</xref>
<sup>)</sup>, as well as various lifestyle modifications, including physical exercise
training<sup>(</sup>
<xref rid="ref23" ref-type="bibr">
<sup>23</sup>
</xref>
<sup>)</sup>. Taken together, our study suggests that the endothelial functional
improvements because of CF intake are similar in effect size, or even greater, compared
with established primary and secondary preventive strategies<sup>(</sup>
<xref rid="ref20" ref-type="bibr">
<sup>20</sup>
</xref>
<sup>&#x02013;</sup>
<xref rid="ref22" ref-type="bibr">
<sup>22</sup>
</xref>
<sup>)</sup>.</p></sec><sec id="sec3-2" sec-type="general"><title>
<italic>Cocoa flavanol</italic> intake decreases blood pressure, vascular stiffness and
cholesterol</title><p>Throughout middle and old age, BP is strongly and directly related to cardiovascular (and
overall) mortality, without any evidence of a threshold down to at least 115/75 mmHg<sup>(</sup>
<xref rid="ref24" ref-type="bibr">
<sup>24</sup>
</xref>
<sup>)</sup>. Dividing people into &#x02018;hypertensives&#x02019; and &#x02018;normotensives&#x02019; is common practice,
but it is problematic as there are now sufficient trial data to show a statistically
significant risk reduction when decreasing the BP even in &#x02018;normotensive&#x02019; individuals,
without known vascular disease<sup>(</sup>
<xref rid="ref25" ref-type="bibr">
<sup>25</sup>
</xref>
<sup>)</sup>. In this context, the risk reduction is rather due to the decrease in BP
<italic>per se</italic>, and there seems to be little or no difference between commonly
used BP-lowering medications for primary prevention of CVD<sup>(</sup>
<xref rid="ref26" ref-type="bibr">
<sup>26</sup>
</xref>
<sup>)</sup>. The results in the present study show that CF intake led to a significant
decrease in SBP and DBP in healthy individuals. This decrease in BP was detected in
central and peripheral arteries. The effect size in our current study (a decrease of
in-office BP of 4&#x000b7;4/3&#x000b7;9 mmHg (SBP/DBP)) was comparable to that described in a
meta-analysis (comparison of CF intake with true CF-free controls using a blinded study
design in patients with CVD or subjects being at risk for CVD (3&#x000b7;7/2&#x000b7;7 mmHg)<sup>(</sup>
<xref rid="ref5" ref-type="bibr">
<sup>5</sup>
</xref>
<sup>,</sup>
<xref rid="ref27" ref-type="bibr">
<sup>27</sup>
</xref>
<sup>)</sup>) and approaches the BP-lowering effect sizes observed by typical BP-lowering
medications<sup>(</sup>
<xref rid="ref28" ref-type="bibr">
<sup>28</sup>
</xref>
<sup>)</sup>.</p><p>So far, no other study of this scale has addressed whether or not flavanols can decrease
BP in healthy subjects with normal BP at the beginning of the study. The parallel changes
in PWV and aortic augmentation are consistent with the notion that an improved elasticity
of arteries or arterial unloading may be related to SBP lowering. The strong association
between ageing and increases in PWV as a marker for vascular stiffness supports that PWV
is a marker of vascular age<sup>(</sup>
<xref rid="ref29" ref-type="bibr">
<sup>29</sup>
</xref>
<sup>)</sup>. In our study, the PWV significantly decreased toward values that are usually
seen in persons several years younger. The parallel changes in central BP and AIX suggest
that this may have positive effects on cardiac function. Future studies will have to
verify the biological relevance of such findings in the context of longer-term
investigations and characterise the mechanisms involved. In the context of the present
study, we cannot mechanistically dissect whether or not the CF intake-induced change in
PWV may be primarily caused by a softening of the aorta and large vessels or are secondary
to alterations in cardiac stroke volume, changes in central and peripheral BP or because
of alterations in the total peripheral resistance. (We have addressed the effect of CF on
haemodynamics in much more detail in a recent study<sup>(</sup>
<xref rid="ref30" ref-type="bibr">
<sup>30</sup>
</xref>
<sup>)</sup>.)</p><p>In middle- and old age, and at all BP levels, high plasma cholesterol is positively
associated with IHD mortality<sup>(</sup>
<xref rid="ref31" ref-type="bibr">
<sup>31</sup>
</xref>
<sup>)</sup>. Depending on age, a decrease in total cholesterol of 1 mmol/l was associated
in middle-aged individuals with a decreased risk of IHD mortality by 50 %. We here show in
healthy volunteers that CF may be able to decrease total and LDL-cholesterol by 0&#x000b7;2 mmol/l
over 1 month. A meta-analysis investigating the effects of cocoa products on lipids in
diverse populations suggested an overall total and LDL-cholesterol-lowering effect of 0&#x000b7;2
mmol/l but no significant effect on HDL-cholesterol<sup>(</sup>
<xref rid="ref32" ref-type="bibr">
<sup>32</sup>
</xref>
<sup>)</sup>. Overall, these outcomes were confirmed by a more recent meta-analysis
including fourteen studies<sup>(</sup>
<xref rid="ref4" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>)</sup>. The results differed from the first meta-analysis<sup>(</sup>
<xref rid="ref32" ref-type="bibr">
<sup>32</sup>
</xref>
<sup>)</sup> in so far as they demonstrated a small, but significant, increase in
HDL-cholesterol in longer-term studies<sup>(</sup>
<xref rid="ref4" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>)</sup>, which is consistent with our current study, thus supporting that CF may be
capable of improving blood lipids in healthy volunteers.</p></sec><sec id="sec3-3" sec-type="general"><title>Primary prevention, cardiovascular health and dietary guidelines</title><p>By applying the Framingham framework of risk assessment to our data set, it can be
demonstrated that our study population was indeed healthy and at low risk for CHD (which
is defined as a 10-year risk to develop CHD of &#x0003c;10 %, compared with 3&#x000b7;4 % in the
present study). More importantly, it can be estimated that CF intake has the potential to
reduce the 10-year risk of CV morbidity and mortality even in this healthy cohort by 20&#x02013;30
% and 30&#x02013;40 % (percent relative to baseline value), respectively. Naturally, such
estimates would be based on the assumption that outcomes in terms of efficacy and safety
would persist over years of chronic CF consumption. Thus, although the application of
Framingham risk scoring in this context should be interpreted with some caution, as our
study was limited with regard to scope and duration, the outcomes of this assessment
provide a useful basis for initial assessments of the potential of CF in the context of
primary CVD prevention, and for data interpretations and discussions in the light of
potential future studies.</p></sec><sec id="sec3-4" sec-type="general"><title>Conclusion</title><p>The outcomes of the Flaviola Health study, a CF-based dietary intervention trial in
healthy middle-aged men and women, demonstrate improvements in accredited surrogates of
cardiovascular risk, including indices of vascular function and metabolism. Our findings
support the notion that CF intake has the potential to support the maintenance of
cardiovascular health. Furthermore, our data add to the accumulating body of evidence
regarding the health benefits of dietary flavanols and procyanidins in general, thus
contributing to evidence-based assessments of potential future dietary guidelines for
these bioactives.</p></sec></sec></body><back><ack id="ack1"><title>Acknowledgements</title><p>C. H., H. S., J. P. E. S., G. C. G. K., A. R. M., M. W. M. and M. K. were senior
investigators in the Flaviola research consortium of the European Union (FP7-KBBE-2008-2B).
C. H., J. P. E. S. and A. R. M. are participants of the EU-funded COST Action FA1403
POSITIVe (interindividual variation in response to consumption of plant food bioactives and
determinants involved). Additional funding was provided by the Deutsche
Forschungsgemeinschaft (KE405/5-1 to M. K. and FOR809 TP7 Me1821/3-1 to M. W. M. and MK),
and through an unrestricted grant by MARS Inc. MARS Inc. also provided the standardised test
drinks used in this investigation.</p><p>C. H., R. S., M. K., M. W. M. and H. S. designed research; R. S., I. H., D. F., D. S., A.
R. M., G. G. C. K., R. W. and J. P. E. S. conducted the research; R. S., C. H., A. R. M., D.
S., I. H., D. F., G. G. C. K., J. P. E. S. and R. W. analysed data; H. S. provided test
drinks on behalf of Mars Inc.; C. H., H. S. and M. K. wrote the paper; M. K., M. W. M., H.
S. and C. H. had primary responsibility for final content. All authors read and approved the
final manuscript.</p><p>H. S. is employed by MARS Inc., a member of the Flaviola research consortium and a company
engaged in flavanol research and flavanol-related commercial activities. None of the other
authors has a conflict of interest to declare other than stated above.</p></ack><ref-list id="refs"><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal">
<name><surname>Heiss</surname><given-names>C</given-names></name>, <name><surname>Dejam</surname><given-names>A</given-names></name>, <name><surname>Kleinbongard</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Vascular effects of cocoa
rich in flavan-3-ols</article-title>. <source>JAMA</source>
<volume>290</volume>, <fpage>1030</fpage>&#x02013;<lpage>1031</lpage>.<pub-id pub-id-type="pmid">12941674</pub-id></mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal">
<name><surname>Heiss</surname><given-names>C</given-names></name>, <name><surname>Keen</surname><given-names>CL</given-names></name> &#x00026; <name><surname>Kelm</surname><given-names>M</given-names></name> (<year>2010</year>) <article-title>Flavanols and cardiovascular disease
prevention</article-title>. <source>Eur Heart J</source>
<volume>31</volume>, <fpage>2583</fpage>&#x02013;<lpage>2592</lpage>.<pub-id pub-id-type="pmid">20852295</pub-id></mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal">
<name><surname>Schroeter</surname><given-names>H</given-names></name>, <name><surname>Heiss</surname><given-names>C</given-names></name>, <name><surname>Balzer</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>(-)-Epicatechin mediates
beneficial effects of flavanol-rich cocoa on vascular function in
humans</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>103</volume>, <fpage>1024</fpage>&#x02013;<lpage>1029</lpage>.<pub-id pub-id-type="pmid">16418281</pub-id></mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal">
<name><surname>Hooper</surname><given-names>L</given-names></name>, <name><surname>Kay</surname><given-names>C</given-names></name>, <name><surname>Abdelhamid</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Effects of chocolate,
cocoa, and flavan-3-ols on cardiovascular health: a systematic review and meta-analysis
of randomized trials</article-title>. <source>Am J Clin Nutr</source>
<volume>95</volume>, <fpage>740</fpage>&#x02013;<lpage>751</lpage>.<pub-id pub-id-type="pmid">22301923</pub-id></mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal">
<name><surname>Ried</surname><given-names>K</given-names></name>, <name><surname>Sullivan</surname><given-names>TR</given-names></name>, <name><surname>Fakler</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Effect of cocoa on blood
pressure</article-title>. <source>Cochrane Database Syst Rev</source>
<volume>8</volume>, CD008893.</mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal">
<name><surname>Desideri</surname><given-names>G</given-names></name>, <name><surname>Kwik-Uribe</surname><given-names>C</given-names></name>, <name><surname>Grassi</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Benefits in cognitive
function, blood pressure, and insulin resistance through cocoa flavanol consumption in
elderly subjects with mild cognitive impairment: the Cocoa, Cognition, and Aging (CoCoA)
study</article-title>. <source>Hypertension</source>
<volume>60</volume>, <fpage>794</fpage>&#x02013;<lpage>801</lpage>.<pub-id pub-id-type="pmid">22892813</pub-id></mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal">
<collab>Efsa Panel on Dietetic Products N &#x00026; Allergies</collab> (<year>2012</year>)
<article-title>Guidance on the scientific requirements for health claims related to
antioxidants, oxidative damage and cardiovascular health</article-title>. <source>EFSA J</source>
<volume>9</volume>, <fpage>2474</fpage>.</mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal">
<name><surname>D&#x02019;Agostino</surname><given-names>RB</given-names><suffix>Sr.</suffix></name>, <name><surname>Vasan</surname><given-names>RS</given-names></name>, <name><surname>Pencina</surname><given-names>MJ</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>General cardiovascular
risk profile for use in primary care: the Framingham Heart Study</article-title>.
<source>Circulation</source>
<volume>117</volume>, <fpage>743</fpage>&#x02013;<lpage>753</lpage>.<pub-id pub-id-type="pmid">18212285</pub-id></mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal">
<name><surname>Adamson</surname><given-names>GE</given-names></name>, <name><surname>Lazarus</surname><given-names>SA</given-names></name>, <name><surname>Mitchell</surname><given-names>AE</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>HPLC method for the
quantification of procyanidins in cocoa and chocolate samples and correlation to total
antioxidant capacity</article-title>. <source>J Agric Food Chem</source>
<volume>47</volume>, <fpage>4184</fpage>&#x02013;<lpage>4188</lpage>.<pub-id pub-id-type="pmid">10552788</pub-id></mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal">
<name><surname>Heiss</surname><given-names>C</given-names></name>, <name><surname>Jahn</surname><given-names>S</given-names></name>, <name><surname>Taylor</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Improvement of endothelial
function with dietary flavanols is associated with mobilization of circulating
angiogenic cells in patients with coronary artery disease</article-title>. <source>J Am
Coll Cardiol.</source>
<volume>56</volume>, <fpage>218</fpage>&#x02013;<lpage>224</lpage>.<pub-id pub-id-type="pmid">20620742</pub-id></mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal">
<name><surname>Horn</surname><given-names>P</given-names></name>, <name><surname>Amabile</surname><given-names>N</given-names></name>, <name><surname>Angeli</surname><given-names>FS</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Dietary flavanol
intervention lowers the levels of endothelial microparticles in coronary artery disease
patients</article-title>. <source>Br J Nutr</source>,
<fpage>1</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal">
<name><surname>Dupont</surname><given-names>WD</given-names></name> &#x00026; <name><surname>Plummer</surname><given-names>WD</given-names></name> (<year>2007</year>) <article-title>PS power and sample size program available for
free on the Internet</article-title>. <source>Controlled Clin Trials</source>
<volume>18</volume>, <fpage>274</fpage>.</mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal">
<name><surname>Van Bortel</surname><given-names>LM</given-names></name>, <name><surname>Laurent</surname><given-names>S</given-names></name>, <name><surname>Boutouyrie</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Expert consensus document
on the measurement of aortic stiffness in daily practice using carotid-femoral pulse
wave velocity</article-title>. <source>J Hypertens</source>
<volume>30</volume>, <fpage>445</fpage>&#x02013;<lpage>448</lpage>.<pub-id pub-id-type="pmid">22278144</pub-id></mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal">
<name><surname>Mulligan</surname><given-names>AA</given-names></name>, <name><surname>Luben</surname><given-names>RN</given-names></name>, <name><surname>Bhaniani</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>A new tool for converting
food frequency questionnaire data into nutrient and food group values: FETA research
methods and availability</article-title>. <source>BMJ Open</source>
<volume>4</volume>, e004503.</mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal">
<name><surname>Vogiatzoglou</surname><given-names>A</given-names></name>, <name><surname>Mulligan</surname><given-names>AA</given-names></name>, <name><surname>Luben</surname><given-names>RN</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Assessment of the dietary
intake of total flavan-3-ols, monomeric flavan-3-ols, proanthocyanidins and theaflavins
in the European Union</article-title>. <source>Br J Nutr</source>,
<fpage>1</fpage>&#x02013;<lpage>11</lpage>.</mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal">
<name><surname>Ottaviani</surname><given-names>JI</given-names></name>, <name><surname>Momma</surname><given-names>TY</given-names></name>, <name><surname>Kuhnle</surname><given-names>GK</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Structurally related
(-)-epicatechin metabolites in humans: Assessment using de novo chemically synthesized
authentic standards</article-title>. <source>Free Radic Biol Med</source>
<volume>52</volume>, <fpage>1403</fpage>&#x02013;<lpage>1412</lpage>.<pub-id pub-id-type="pmid">22240152</pub-id></mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal">
<name><surname>Perk</surname><given-names>J</given-names></name>, <name><surname>De Backer</surname><given-names>G</given-names></name>, <name><surname>Gohlke</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>European Guidelines on
cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint
Task Force of the European Society of Cardiology and Other Societies on Cardiovascular
Disease Prevention in Clinical Practice (constituted by representatives of nine
societies and by invited experts). Developed with the special contribution of the
European Association for Cardiovascular Prevention &#x00026; Rehabilitation
(EACPR)</article-title>. <source>Eur Heart J</source>
<volume>33</volume>, <fpage>1635</fpage>&#x02013;<lpage>1701</lpage>.<pub-id pub-id-type="pmid">22555213</pub-id></mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal">
<name><surname>Yang</surname><given-names>Q</given-names></name>, <name><surname>Cogswell</surname><given-names>ME</given-names></name>, <name><surname>Flanders</surname><given-names>WD</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Trends in cardiovascular
health metrics and associations with all-cause and CVD mortality among US
adults</article-title>. <source>JAMA</source>
<volume>307</volume>, <fpage>1273</fpage>&#x02013;<lpage>1283</lpage>.<pub-id pub-id-type="pmid">22427615</pub-id></mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal">
<name><surname>Ras</surname><given-names>RT</given-names></name>, <name><surname>Streppel</surname><given-names>MT</given-names></name>, <name><surname>Draijer</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Flow-mediated dilation and
cardiovascular risk prediction: a systematic review with meta-analysis</article-title>.
<source>Int J Cardiol</source>
<volume>168</volume>, <fpage>344</fpage>&#x02013;<lpage>351</lpage>.<pub-id pub-id-type="pmid">23041097</pub-id></mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal">
<name><surname>Reriani</surname><given-names>MK</given-names></name>, <name><surname>Dunlay</surname><given-names>SM</given-names></name>, <name><surname>Gupta</surname><given-names>B</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Effects of statins on
coronary and peripheral endothelial function in humans: a systematic review and
meta-analysis of randomized controlled trials</article-title>. <source>Eur J Cardiovasc
Prev Rehabil</source>
<volume>18</volume>, <fpage>704</fpage>&#x02013;<lpage>716</lpage>.<pub-id pub-id-type="pmid">21450596</pub-id></mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal">
<name><surname>Anderson</surname><given-names>TJ</given-names></name>, <name><surname>Elstein</surname><given-names>E</given-names></name>, <name><surname>Haber</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2000</year>) <article-title>Comparative study of
ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated
vasodilation in patients with coronary disease (BANFF study)</article-title>. <source>J
Am Coll Cardiol</source>
<volume>35</volume>, <fpage>60</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">10636260</pub-id></mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal">
<name><surname>Ye</surname><given-names>Y</given-names></name>, <name><surname>Zhao</surname><given-names>X</given-names></name>, <name><surname>Zhai</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Effect of high-dose statin
versus low-dose statin plus ezetimibe on endothelial function: a meta-analysis of
randomized trials</article-title>. <source>J Cardiovasc Pharmacol Ther</source>
<volume>17</volume>, <fpage>357</fpage>&#x02013;<lpage>365</lpage>.<pub-id pub-id-type="pmid">22710021</pub-id></mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal">
<name><surname>Schuler</surname><given-names>G</given-names></name>, <name><surname>Adams</surname><given-names>V</given-names></name> &#x00026; <name><surname>Goto</surname><given-names>Y</given-names></name> (<year>2013</year>) <article-title>Role of exercise in the prevention of
cardiovascular disease: results, mechanisms, and new perspectives</article-title>.
<source>Eur Heart J</source>
<volume>34</volume>, <fpage>1790</fpage>&#x02013;<lpage>1799</lpage>.<pub-id pub-id-type="pmid">23569199</pub-id></mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal">
<name><surname>Lewington</surname><given-names>S</given-names></name>, <name><surname>Clarke</surname><given-names>R</given-names></name>, <name><surname>Qizilbash</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>Age-specific relevance of
usual blood pressure to vascular mortality: a meta-analysis of individual data for one
million adults in 61 prospective studies</article-title>. <source>Lancet</source>
<volume>360</volume>, <fpage>1903</fpage>&#x02013;<lpage>1913</lpage>.<pub-id pub-id-type="pmid">12493255</pub-id></mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal">
<name><surname>Law</surname><given-names>M</given-names></name> (<year>2012</year>) <article-title>A change in paradigm: lowering blood pressure
in everyone over a certain age</article-title>. <source>Ann Med</source>
<volume>44,</volume>, <issue>Suppl. 1</issue>,
<fpage>S30</fpage>&#x02013;<lpage>S35</lpage>.<pub-id pub-id-type="pmid">22713146</pub-id></mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal">
<name><surname>Fretheim</surname><given-names>A</given-names></name>, <name><surname>Odgaard-Jensen</surname><given-names>J</given-names></name>, <name><surname>Brors</surname><given-names>O</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Comparative effectiveness
of antihypertensive medication for primary prevention of cardiovascular disease:
systematic review and multiple treatments meta-analysis</article-title>. <source>BMC Med</source>
<volume>10</volume>, <fpage>33</fpage>.<pub-id pub-id-type="pmid">22480336</pub-id></mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal">
<name><surname>Egan</surname><given-names>BM</given-names></name>, <name><surname>Laken</surname><given-names>MA</given-names></name>, <name><surname>Donovan</surname><given-names>JL</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Does dark chocolate have a
role in the prevention and management of hypertension?: commentary on the
evidence</article-title>. <source>Hypertension</source>
<volume>55</volume>, <fpage>1289</fpage>&#x02013;<lpage>1295</lpage>.<pub-id pub-id-type="pmid">20404213</pub-id></mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal">
<collab>Turnbull F &#x00026; Blood Pressure Lowering Treatment Trialists
Collaboration</collab> (<year>2003</year>) <article-title>Effects of different
blood-pressure-lowering regimens on major cardiovascular events: results of
prospectively-designed overviews of randomised trials</article-title>. <source>Lancet</source>
<volume>362</volume>, <fpage>1527</fpage>&#x02013;<lpage>1535</lpage>.<pub-id pub-id-type="pmid">14615107</pub-id></mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal">
<name><surname>Nilsson</surname><given-names>PM</given-names></name> (<year>2014</year>) <article-title>Hemodynamic Aging as the Consequence of
Structural Changes Associated with Early Vascular Aging (EVA)</article-title>.
<source>Aging Dis</source>
<volume>5</volume>, <fpage>109</fpage>&#x02013;<lpage>113</lpage>.<pub-id pub-id-type="pmid">24729936</pub-id></mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal">
<name><surname>Heiss</surname><given-names>C</given-names></name>, <name><surname>Sansone</surname><given-names>R</given-names></name>, <name><surname>Karimi</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Impact of cocoa flavanol
intake on age-dependent vascular stiffness in healthy men: a randomized, controlled,
double-masked trial</article-title>. <source>Age (Dordr)</source>
<volume>37</volume>, <fpage>9794</fpage>.<pub-id pub-id-type="pmid">26013912</pub-id></mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="journal">
<collab>Prospective Studies Collaboration</collab>, <name><surname>Lewington</surname><given-names>S</given-names></name>, <name><surname>Whitlock</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Blood cholesterol and
vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data
from 61 prospective studies with 55 000 vascular deaths</article-title>. <source>Lancet</source>
<volume>370</volume>, <fpage>1829</fpage>&#x02013;<lpage>1839</lpage>.<pub-id pub-id-type="pmid">18061058</pub-id></mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal">
<name><surname>Tokede</surname><given-names>OA</given-names></name>, <name><surname>Gaziano</surname><given-names>JM</given-names></name> &#x00026; <name><surname>Djousse</surname><given-names>L</given-names></name> (<year>2011</year>) <article-title>Effects of cocoa products/dark chocolate on
serum lipids: a meta-analysis</article-title>. <source>Eur J Clin Nutr</source>
<volume>65</volume>, <fpage>879</fpage>&#x02013;<lpage>886</lpage>.<pub-id pub-id-type="pmid">21559039</pub-id></mixed-citation></ref></ref-list></back></article>